| Trial ID: | L3388 |
| Source ID: | NCT04159766
|
| Associated Drug: |
Nly01
|
| Title: |
A Study With NLY01 in Subjects With Type 2 Diabetes
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Type2 Diabetes|Diabetes Mellitus, Type 2
|
| Interventions: |
DRUG: NLY01|DRUG: Placebo
|
| Outcome Measures: |
Primary: Number of participants with Treatment Emergent Adverse Events, 35 days|Number of Incidences of Adverse Events, 35 days|Plasma glucose, Change of fasting glucose profiles, 24 hours|Change in serum insulin, Change in 24 hour serum insulin, 24 hours|Change in plasma glucagon, Change in 24 hour plasma glucagon concentrations, 24 hours |
|
| Sponsor/Collaborators: |
Sponsor: Neuraly, Inc.
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE2
|
| Enrollment: |
20
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT
|
| Start Date: |
2019-10-16
|
| Completion Date: |
2020-12-04
|
| Results First Posted: |
|
| Last Update Posted: |
2021-03-02
|
| Locations: |
Profil Institute fur Stoffwechselforschung GmbH, Neuss, D-41460, Germany|Profil Institute, Neuss, D-41460, Germany
|
| URL: |
https://clinicaltrials.gov/show/NCT04159766
|
